Arbor Vita Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs and diagnostics addressing disease through a new family of targets, PDZ proteins. PDZ proteins are critical elements that organize and regulate many signaling pathways in human cells. The disruption of PDZ interactions has recently begun to be appreciated as providing a novel way to control multiple signaling cascades in complex diseases. AVC is pioneering the development of therapeutics and diagnostics through their unique understanding of the role of PDZs in cell signaling and disease. The company is tackling major health issues including cancer; infectious diseases such as influenza; stroke and cardiovascular disease.

h5n1 test  
HPV test Presentation
May 8–14, 2009
AVC Presents Posters at 25th International Papillomavirus Conference in Malmö, Sweden
AVantage HPV E6 Diagnostic Poster

Cervical Cancer Therapeutic Poster
Press Release
April 7, 2009
Arbor Vita Receives FDA Clearance of its AVantage™ A/H5N1 Flu Diagnostic—First Rapid Test for Avian Influenza in Humans
avian flu test Press Release
November 14, 2008
Arbor Vita Presents New Data on Cancer Diagnostic at EUrogin
Press Release
November 10, 2008
Arbor Vita Announces a Collaboration and License Agreement with BD for the Development of a Diagnostic Test for Cervical Cancer
HPV test Press Release
September 8, 2008
Arbor Vita and WRAIR Sign CRADA for Traumatic Brain Injury (TBI) Collaboration